Scientific Programme

Click on the button below to download the final programme:




The lecture hall “Jesuitensaal” is located on the second floor of the conference venue.

8.00AM-8.10AMWelcome address Organizing committee
8.10AM-8.30AMKeynote lecture: Bacteria fuel malignant inflammation and disease activity in CTCLNiels Ødum, Copenhagen, Denmark
8.30AM-8.50AMMicrobial triggers and clonal evolution in CTCL pathogenesisSergei Koralov, New York, NY, USA
8.50AM-9.10AMChronic T cell activation by CD1a and Staphylococcal lipidsAnnemieke de Jong, New York, NY, USA
9.10AM-9.30AMAhR signaling drives defective type I IFN signaling in mycosis fungoidesRachael Clark, Boston, MA, USA
9.30AM-9.50AMInfectious and environmental drivers of CTCLLarisa Geskin, New York, NY, USA
10.30AM-10.50AMThe micromilieu in CTCL: From inflammation over tumor progress to antitumoral response
Gabor Dobos, Berlin, Germany
10.50AM-11.10AMTargeting immunosuppressive macrophages in the tumor microenvironment of CTCLChristiane Querfeld, Duarte, CA, USA
11.10AM-11.30AMThe role of cancer-associated fibroblasts in MFEmmilia Hodak, Tel Aviv, Israel
11.30AM-11.50PMADCC in lymphoma treatment – A spotlight on NK cells?Emmanuella Guenova, Lausanne, Switzerland
1.00PM-1.20PMTowards a better understanding of the CTCL cellular and molecular landscapeMuzlifah Haniffa, Newcastle, UK
1.20PM-1.40PMInsights into pathogenesis and translational strategies for CTCLMichael Girardi, New Haven, CT, USA
1.40PM-2.00PMAn individualized approach to therapy of advanced MF in the era of personalized medicineOleg Akilov, Pittsburgh, PA, USA
2.00AM-2.20AMIndolent vs. aggressive diseasePatrick M. Brunner, New York, NY, USA
2.40PM-3.00PMCTCL: unraveling the mechanisms of long-term disease controlAdèle de Masson, Paris, France
3.00PM-3.20PMNew treatment targetsMartine Bagot, Paris, France
3.20PM-3.40PMTherapeutic mechanisms in CTCL: Lessons learnt from photo(chemo)therapyPeter Wolf, Graz, Austria
3.40PM-4.00PMThe association of CTCL with inflammatory skin disorders and its treatments - True causality or misdiagnosis?Shamir Geller, New York, NY, USA
4.00PM-4.15PMConcluding remarks and awards
01.00PM - 04.00PMPre-Meeting Symposium: Research Techniques in Atopic Dermatitis
(Registration via IEC website required)
International Eczema Council
04.30PM - 04.40PMWelcome Address

Welcome Words from the president of the Austrian Academy of Sciences
Organizing Committee

Heinz Faßmann
04.40PM -05.00PMSetting the StageGeorg Stingl,
Vienna, Austria
05.00PM - 05.30PMKeynote lecture
“Immune system-driven skin fibrosis”
Richard Flavell,
New Haven, CT, USA
05.30PM - 06.00PMType 2 immunity across diseasesBart Lambrecht,
Ghent, Belgium
06.00PM - 07.00PMOral presentations from selected abstracts

Spatial proteomic and transcriptomic profiling of lichen planus reveals a unique inflammatory
Matthew Vesely, New Haven, USA

Targeting the IL-15 signaling pathway prevents the formation of cutaneous TRM and
limits flare-ups of allergic contact dermatitis
Roxane Cuzin, Lyon, France

Effectivity of mTOR inhibition in cutaneous sarcoidosis
Anna Redl, Vienna, Austria

Bidirectional TGF-beta signaling between CD8+ T cells and melanocytes determines
melanocyte death in vitiligo, rescued by small-molecule receptor blocker
Shany Sherman, Worcester, USA

The Phase 2 MIRA trial of the IL-17A- and IL-17F-inhibiting Nanobody® sonelokimab in patients
with active, moderate-to-severe hidradenitis suppurativa (HS): Week 12 results
Brian Kirby, Dublin, Ireland
07.00PM - 10.00PMReception and poster viewingMore information
08.00 AM – 09.30 AMSponsored Breakfast SymposiumMore information
09.30 AM – 09.45 AMBREAK
09.45 AM – 10.15 AMInnate immunity in the skinMichel Gilliet,
Lausanne, Switzerland
10.15 AM – 10.45 AMThe microbiome in inflammatory skin diseasesHeidi Kong,
Bethesda, MD, USA
10.45 AM – 11.15 AMDeveloping a human skin cell atlasMuzlifah Haniffa,
Newcastle, United Kingdom
11.15 AM – 11.45 AMOral presentations from selected abstracts

Skin CD69+CD62L+ TRM, a subset with renewal capacity gives rise to CD103+CD49a+ TRM
Wenning Zheng, Copenhagen, Denmark

IL-9 sensitizes human pathogenic Th2 cells to pro-inflammatory IL-18 signals in atopic dermatitis
Stefanie Schärli, Bern, Switzerland
11.45 AM – 12.00 PMBREAK
12.00 PM – 01.30 PMSponsored Lunch SymposiumMore information
01.30 PM – 01.45 PMBREAK
01.45 PM – 02.15 PMMitochondrial ROS and cytoplasmic nucleic acid sensing set the inflammatory tone in human skinRachael Clark,
Boston, MA, USA
02.15 PM – 02.45 PMCutaneous T cell compartments in health and immunodeficiencyGeorg Stary,
Vienna, Austria
02.45 PM – 03.15 PMChronic inflammation – what we learn from cutaneous lymphomasPatrick M. Brunner,
New York, NY, USA
03.15 PM – 03.45 PMOral presentations from selected abstracts

Squamous Cell Carcinoma in patients with Recessive Dystrophic Epidermolysis Bullosa is associated with dysregulated T cell function
Iris K. Gratz, Salzburg, Austria

Influence of dupilumab on HSV-specific immune response in atopic dermatitis
Stephan Traidl, Hannover, Germany
03.45 PM – 04.15 PMCOFFEE BREAK
04.15 PM – 04.45 PMDissecting the role of IL-13 in health and diseaseJohannes U. Mayer,
Marburg, Germany
04.45 PM – 05.15 PMJanus kinases in inflammationMassimo Gadina,
Bethedsa, MD, USA
05.15 PM – 05.45 PMPsoriasisJohann Gudjonsson, Ann Arbor, MI, USA
05.45 PM – 06.15 PMNewly identification of a CXCR6+ pathogenic skin-resident CD4+ T cell subset in a mouse model of allergic dermatitis that requires CXCL16 for its maintenanceKenji Kabashima,
Kyoto, Japan
07.30 PM - 11.00PMConference Networking Event

Bus transfer: 06.45pm & 07.15pm at Weiskirchnerstraße 3, 1010 Vienna
(between MAK & the Stadtpark)
More information
08.00 AM – 09.30 AMOral presentations from selected abstracts

AhR agonism by tapinarof regulates TH2 and TH17 cell function in human skin
Fabian Luther, Bern, Switzerland

Effect of Ruxolitinib Cream on Biomarkers of Atopic Dermatitis
Susan Smith, Wilmington, USA

Treatment with the oral CCR4 antagonist RPT193 results in meaningful changes in cutaneous biomarkers detected by transcriptomic profiling of tape strips
Ester Del Duca, New York, USA

Spesolimab Use in Treatment of Severe Pyoderma Gangrenosum
Sophie Guenin, New York, USA

Efficacy and safety of amlitelimab (an anti-OX40 ligand antibody) in patients with moderate-to-severe atopic dermatitis (AD): 24-week results from a Phase 2b trial (STREAM-AD)
Wendell Valdecantos, Cambridge, USA

EVO756 is a novel MRGPRX2 antagonist that potently inhibits human mast cell degranulation in response to multiple agonists – potential treatment for CSU and beyond
Hans E Hofland, Palo Alto, USA

Lebrikizumab reduces systemic inflammation in serum of patients with moderate-to-severe atopic dermatitis
Emma Guttman-Yassky, New York, NY, USA
09.30 AM – 09.45 AMBREAK
09.45 AM – 10.15 AMNeuronal immunology interactionsDan Kaplan,
Pittsburgh, PA, USA
10.15 AM – 10.45 AMItch and neuroinflammationBrian Kim,
New York, NY, USA
10:45 PM– 11:15 AM"Of mice and men” - A Tale of Inflammatory Skin DiseasesNicole Ward,
Nashville, TN, USA
11:15 AM – 11.45 AMOral presentations from selected abstracts

Human epidermal Langerhans cells emigrate and induce a tolerogenic immune response in response to tick feeding and tick-borne pathogens
Lisa Kleissl, Vienna, Austria

Detection of skin allergy biomarkers for point-of-care diagnosis of contact dermatitis
Marine-Alexia Lefevre, Bron, France
11.45 PM – 12.00 PMBREAK
12.00 PM – 01.30 PMSponsored Lunch SymposiumMore information
01.30 PM – 01.45 PMBREAK
01.45 PM – 02.15 PMAdvances in atopic dermatitisAlan Irvine,
Dublin, Ireland
02.15 PM – 02.45 PMAlopecia areataRalf Paus,
Miami, FL, USA
02.45 PM – 03.15 PMAtopic dermatitis & alopecia areata: Common mechanisms and targetsEmma Guttman,
New York, NY, USA
03.15 PM – 03.45 PMOral presentations from selected abstracts

Effectiveness of OR-101, a Next Generation Highly Selective JAK3 Inhibitor, in a Humanized Murine Model of Alopecia Areata
Marta Bertolini, Münster, Germany

Non-lesional type 2 and type 17/22 immune activation precedes lesional type 1-associated inflammation in skin of vitiligo patients Patrick M. Brunner, New York, USA
03.45 PM – 04.15 PMCOFFEE BREAK
04.15 PM – 04.45 PMOral presentations from selected abstracts

Dupilumab-associated head and neck dermatitis shows a pronounced type 22 immune signature mediated by oligoclonally expanded T cells
Christine Bangert, Vienna, Austria

Tape strips detect molecular alterations and cutaneous biomarkers in hidradenitis suppurativa skin
Kristina Navrazhina, New York, USA

04.45 PM – 05.15 PMHidradenitis suppurativaJames G. Krueger,
New York, NY, USA
05.15 PM – 05.45 PMEmerging opportunities in vitiligoJohn Harris,
Worcester, MA, USA
05.45 PM – 06.45 PMOral presentations from selected abstracts

Immune-mesenchymal crosstalk contribute to the expansion of autoreactive plasma cells in the tertiary lymphoid structures in Hidradenitis Suppurativa
Catherine Lu, New York, USA

Tape Strip Genomic Profiling of Lesional and -lesional Atopic Dermatitis Skin Identifies Early and Progressive Normalization Following Treatment With Abrocitinib
Madeline Kim, New York, USA

Deciphering dysfunctional regultory T cells in atopic dermatitis
Hyun Je Kim, Seoul, South Korea

Efficacy, Safety, and Tolerability of GSK1070806, an Anti–IL-18 Monoclonal Antibody, in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Study
John Kelly, Collegeville, USA
06.45 PM - 07.00 PMBREAK
07.00 PM - 8.30 PMSponsored Dinner SymposiumMore information
08.00 AM - 9.30 AMOral presentations from selected abstracts

Single cell transcriptome revealed the role of CCL19+ inflammatory epithelial cells in pemphigus
Yiyi Wang, Chengdu, China

Chronic hand eczema shares a common molecular signature regardless of atopic dermatitis status
Jonathan Bar, New York, USA

Cutaneous lupus single cell analyses reveal critical type I interferon mediated reprogramming of skin stroma
Jeff Gehlhausen, New Haven, USA

Preclinical Ex Vivo and In Vivo Evidence Supporting Selective Inhibition of Tyrosine Kinase 2-Dependent, IL-12-Mediated Signaling as a Novel Pharmacological Strategy for Alopecia Areata Management
Ian M. Catlett, Princeton Pike, USA

A Chronic Inflammatory Environment Revealed In Age Spots From Both European And Asian Volunteers
Constance Alvarez-Duchesne, Aulnay-Sous-Bois, France

Clinical response to IL-22RA1 blockade is associated with reduction of systemic inflammation
Britta Martel, Ballerup, Denmark
09.30 AM – 09.45 AMBREAK
9.45 AM – 10.15 AMAcademic / industry collaboration and perspectivesKristian Reich,
Hamburg-Eppendorf, Germany
10.15 AM – 10.45 AMThe Past, Present, and Future of Cell Therapies for AutoimmunityAimee Payne,
Philadelphia, PA, USA
10.45 AM – 11.15 AMLupus: New DevelopmentsJoseph Merola,
Boston MA, USA
11.15 AM – 11.45 AMThe role of the target tissue in skin autoimmunity: pemphigus as a case studyEli Sprecher,
Tel Aviv, Israel
11.45 PM – 12.00 PMOral presentations from selected abstracts

Scarring alopecia is driven by the collapse of EGFR-protected JAK-STAT1-sensitive stem cell immune privilege
Karoline Strobl, Vienna, Austria
12.00 PM – 12.15 PMBREAK
12.15 PM – 01.45 PMSponsored Lunch SymposiumMore information
01.45 PM – 02.00 PMBREAK
02.00 PM – 02.30 PMArtificial Intelligence in DermatologyPhilipp Tschandl,
Vienna, Austria
02.30 PM – 03.00 PM UrticariaMarcus Maurer,
Berlin, Germany
03.00 PM Award Ceremony & Conference Closing
03.30 PM - 06.30 PMIndustry Satellite EventMore information